Andrew M. Stuart is a Professor at the California Institute of Technology's Division of Engineering and Applied Science. His research bridges computational mathematics, machine learning, and physical modeling, focusing on inverse problems, partial differential equations, and multiscale systems. He has pioneered methodologies integrating Gaussian processes, Kalman inversion, and neural operators for scientific computing. His recent publications highlight innovations in competitive protein dimerization networks, nonlinear Bayesian inference, and operator learning. Articles span applications in materials science, geophysics, and biochemical signal processing, emphasizing data-driven discovery of differential equations and scalable algorithms for high-dimensional problems. Stuart's work addresses challenges in structural error modeling, uncertainty quantification, and graph-based learning, with implications for climate modeling and dynamical systems. Despite extensive contributions, the scraped data does not specify students, awards, or contact details.
جستوجوی استاد و پژوهشگر
استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشیتان را پیدا کنید و با او ارتباط بگیرید.
نمایش ۱۶-۳۰ از ۲٬۴۵۷ استاد راهنما
اطلاعات این پروفایلها از صفحات عمومی دانشگاهها جمعآوری شده و ممکن است بهروز نباشد.
Wengong Jinمشاهده پروفایل
استادیار
Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.
Raul Astudillo Marban is a Postdoctoral Scholar Research Associate in the Department of Computing and Mathematical Sciences at Caltech, hosted by Professor Yisong Yue. He will join MBZUAI as a tenure-track Assistant Professor in August 2025. His research focuses on adaptive learning and decision-making in complex, data-intensive environments, with applications in personalized healthcare, engineering design, and scientific discovery. He earned his Ph.D. in Operations Research and Information Engineering from Cornell University under Professor Peter Frazier and holds an undergraduate degree in Mathematics from the University of Guanajuato and the Center for Research in Mathematics. His work integrates Bayesian optimization and machine learning to address real-world challenges such as protein engineering, plant breeding, and computational biology. Key contributions include steering generative models with experimental data, preferential multi-objective optimization, and cost-aware Bayesian strategies. He has received recognition as a Rising Star in Management Science and Engineering (Stanford) and a Rising Star in Data Science (University of Chicago/UCSD). Recent research highlights include optimizing protein fitness through generative models, active learning in directed evolution, and Bayesian optimization for budget allocation in agriculture. His publications span top venues like NeurIPS, Nature Communications, and TMLR. He actively recruits students/researchers for projects in machine learning and optimization.
Rina Dechter is a Professor of Computer Science at the University of California, Irvine (UCI), affiliated with the Donald Bren School of Information and Computer Sciences (ICS). She specializes in automated reasoning, probabilistic and constraint-based graphical models, and causal inference. Dechter has held leadership roles, including Co-Editor-in-Chief of Artificial Intelligence since 2011 and editorial board memberships in journals such as the Constraint Journal and Journal of Machine Learning Research . Education : Ph.D., Computer Science, University of California, Los Angeles (UCLA) M.S., Applied Mathematics, Weizmann Institute B.S., Mathematics and Statistics, Hebrew University of Jerusalem Research Interests : Dechter’s work focuses on computational aspects of automated reasoning, constraint processing, probabilistic reasoning, and causal inference. She develops efficient algorithms for graphical models, emphasizing tractable reasoning tasks and anytime search strategies. Her recent projects include causal decision-making frameworks funded by a $5M NSF grant. Awards : Presidential Young Investigator Award (1991) AAAI Fellow (1994) ACP Research Excellence Award (2007) ACM Fellow (2013) Elected to the American Academy of Arts & Sciences (2025) Grants & Collaborations : She leads a multi-institutional NSF-funded project on causal foundations of AI decision-making. Her work emphasizes trustworthiness in AI through causal models, with applications in robotics and public health.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Professor Daniel Segrè is a faculty member at Boston University, holding the title of Professor of Biology, Bioinformatics, and Biomedical Engineering. His research focuses on systems biology, microbial ecology, and metabolic engineering, with an emphasis on understanding complex biological networks and their applications in bioenergy and biomedicine. Segrè leads the Segre Lab ( segrelab.bu.edu ), where theoretical and computational approaches are applied to study metabolism, microbial interactions, and synthetic biology. Segrè earned his PhD from the Weizmann Institute of Science, Israel. His work bridges fundamental science and applied engineering, addressing topics such as microbial community dynamics, metabolic pathway design, and environmental microbiome applications. Research Interests: Systems biology of metabolism, evolution of biochemical networks, microbial interactions, bioinformatics, and environmental microbiome engineering. His lab develops computational models (e.g., COMETS) to simulate microbial ecosystems and design synthetic microbial communities for climate change mitigation and bioenergy production. Teaching: Courses include BE 777 (Computational Genomics), BF 821 (Bioinformatics Seminar), and BF 571 (Dynamics and Evolution of Biological Networks). These courses reflect his expertise in integrating computational methods with biological systems analysis.
Britt Adamsonمشاهده پروفایل
دانشیار
Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.
David R. Koesمشاهده پروفایل
دانشیار
David R. Koes is an Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh, affiliated with the School of Medicine. He holds roles such as Associate Director of the Joint CMU-Pitt Computational Biology PhD Program (CPCB) and is involved in multiple graduate programs including Intelligent Systems and Computational Biomedicine. His research focuses on developing computational algorithms and systems for drug discovery, emphasizing open-source software and machine learning applications in biomedical data. Koes teaches courses like MSCBIO2025 (Bioinformatics Programming in Python) and MSCBIO2065 (Scalable Machine Learning for Big Data Biology). He has secured NIH funding (R35GM140753) and collaborated on projects with institutions like NVIDIA and Google Cloud. His lab develops tools such as GNINA, Pharmit, and 3Dmol.js, and actively contributes to open drug discovery initiatives. Education: PhD in Computer Science from Carnegie Mellon University (CMU). Research Interests: Leveraging computation and AI for drug design, molecular docking, pharmacophore modeling, and open science. Specific areas include developing scalable machine learning pipelines, virtual screening systems, and tools for 3D molecular analysis. Grants and Funding: Current NIH R35 grant and prior support from NSF, Relay Therapeutics, and others. His work emphasizes translating computational methods into practical drug discovery solutions. Lab and Teams: Directs a lab focused on computational drug discovery, collaborating with multiple academic and industry partners. Supervises graduate students and postdocs in projects spanning AI-driven drug design, molecular modeling, and software development.
David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.
Prof. Vasilis Ntziachristos is a Professor and Chair of Biological Imaging at the Technical University of Munich (TUM), leading the Institute of Biological and Medical Imaging at the Helmholtz Centre Munich. His research focuses on developing novel optical and optoacoustic imaging techniques for early disease detection, diagnostics, and theranostics. He holds a PhD in Bioengineering from the University of Pennsylvania and previously served as an Assistant Professor at Harvard University and Massachusetts General Hospital. Affiliations: TUM School of Medicine and Health, Helmholtz Munich, Institute of Biological and Medical Imaging. Key Research Themes: Non-invasive imaging methods, molecular imaging, optoacoustic technology, and clinical translation. His work bridges theoretical developments with clinical applications, including advancements in glucose monitoring, cancer imaging, and drug delivery systems. Notable awards include the Leibniz Prize (2013) and the World Molecular Imaging Society Gold Medal (2015). Labs/Teams: Imaging to Sensing I2S, Optoacoustic Mesoscopy, Fluorescence Imaging, and AI in Optoacoustics. Grants/Projects: Involvement in Horizon Europe initiatives and collaborations with TranslaTUM and Helmholtz Munich. Prof. Ntziachristos actively contributes to education via courses like 'Biological Imaging' and 'Introduction to Bioengineering', fostering the next generation of imaging scientists.
Volodymyr Kuleshovمشاهده پروفایل
استادیار
Volodymyr Kuleshov is an Assistant Professor at Cornell Tech and Cornell University's Department of Computer Science. His research focuses on machine learning, particularly generative models, probabilistic methods, and applications in health and sustainability. He co-founded Afresh, an AI startup reducing food waste, and has commercialized genome sequencing work via Moleculo (now part of Illumina). Kuleshov earned his PhD from Stanford University, advised by prominent figures like Stefano Ermon and Serafim Batzoglou. He teaches courses like CS 5785 (Applied Machine Learning) and CS 6785 (Advanced Topics in Machine Learning). His awards include the NSF CAREER Award and Arthur Samuel Best Thesis Award. Education: PhD in Computer Science from Stanford University (2018), advised by Stefano Ermon, Serafim Batzoglou, Michael Snyder, Christopher Re, and Percy Liang. Research Interests: Core ML (generative models, approximate inference), health tech (genome sequencing, clinical decision support), sustainability (AI-driven food waste reduction). Notable projects include Caduceus for DNA sequence modeling and Diffusion Duality theory. Awards: Google Research Scholar Award (2025), Outstanding Paper Award (EMNLP 2023), NIH MIRA Award (2023). Students/Advising: Over 20 advisees across PhD, Master’s, and undergraduate programs, including Edgar Marroquin (PhD) and Charlie Marx (Stanford). Alumni include Allan Bishop (Bloomberg) and Yong Huang (UCI PhD). Labs/Teams: Leads research groups at Cornell Tech focusing on generative AI and its real-world applications. Collaborates with institutions like MILA (Montreal) and DeepMind.
Michael Groll serves as Professor and Chair of Biochemistry at the Technical University of Munich (TUM), where he leads structural biology and enzymology research with a focus on proteasome mechanisms and inhibitor development. His laboratory, located at the Ernst-Otto-Fischer-Str. 8 campus in Garching, maintains active collaborations in drug discovery for cancer and infectious diseases. His primary research domains include proteasome inhibition, enzyme catalysis, and natural product biosynthesis, employing X-ray crystallography, biochemical assays, and bioengineering to dissect molecular mechanisms. Recent work emphasizes AI-guided enzyme optimization, bacterial stress response targeting, and structural characterization of halogenation enzymes, reflecting interdisciplinary approaches bridging chemistry and biology. Analysis of his 2023-2025 publications reveals consistent innovation in proteasome-targeted therapeutics, with 15 high-impact papers featuring structural insights into enzyme-inhibitor complexes and biosynthetic pathways. Key trends include engineering megasynthetases for immunoproteasome inhibitors, optical control of protein degradation, and elucidating metal-dependent mechanisms in antibiotic biosynthesis. No scientific awards were documented in the provided source material. While specific grant details and student mentorship records were not disclosed, his extensive publication record indicates leadership in collaborative research projects involving structural biology and chemical biology methodologies. The Chair of Biochemistry under Prof. Groll operates as a hub for structural enzymology, housing facilities for protein crystallography, enzyme kinetics, and natural product characterization. His team actively contributes to TUM's research ecosystem through partnerships with pharmaceutical groups and international structural biology consortia.
Andrew D. White is an Associate Professor of Chemical Engineering at the Hajim School of Engineering & Applied Sciences, University of Rochester. He holds a PhD from the University of Washington (2013). His research focuses on automating scientific discovery through AI, particularly leveraging large language models (LLMs) and deep learning techniques in chemistry. His lab develops agents that integrate literature analysis, hypothesis generation, and experimental design to advance fields like molecular dynamics and drug discovery. Education: PhD in Chemical Engineering, University of Washington, 2013 BS/MS (not explicitly stated in text, inferred from career timeline) Research Interests: Large language models for scientific automation Deep learning applications in chemistry and materials science Molecular dynamics simulations Scientific agents and autonomous systems Publications: His work includes groundbreaking studies on closed-loop AI systems for chemistry, federated learning in molecular property prediction, and multi-agent systems for drug discovery. Recent highlights include the Robin system and ChemCrow tools. Awards: Recipient of the NSF Career Award (2018), NIH Outstanding Investigator Award (2020), and the Curtis Teaching Award (2019). He also advises biotech companies and serves on the National Academy of Sciences' Chemical Sciences Roundtable. Grants & Funding: Supported by DOE, NSF (multiple grants including CBET-1751471), NIH (R35GM137966), and LLNL projects. Collaborates with institutions like Argonne National Lab and Qubit Pharmaceuticals. Labs & Teams: Leads the White Lab at Rochester and co-founded FutureHouse, a nonprofit advancing AI-driven scientific discovery. Supervises a multidisciplinary team of PhD students and postdocs in computational chemistry, AI, and biophysics.
Martin Burke is the May and Ving Lee Professor for Chemical Innovation and Professor of Chemistry at the University of Illinois Urbana-Champaign , with additional appointments in Biochemistry, Biomedical & Translational Sciences, and multiple campus institutes including the Beckman Institute and the Carl R. Woese Institute for Genomic Biology. Education B.S. Johns Hopkins University , 1998 Ph.D. Harvard University , 2003 M.D. Harvard Medical School , 2003 Research Interests Burke’s program centers on molecular prosthetics : the design, synthesis and application of small molecules that replicate or replace missing or dysfunctional proteins. His group pioneered iterative cross-coupling (ICC) using MIDA-protected haloboronic acids to automate the construction of complex natural products and function-oriented small molecules. Current projects target ion-channel replacement in cystic fibrosis, iron-transport restoration in anemia, and non-toxic antifungals that overcome drug resistance. Scientific Awards & Honors National Academy of Medicine (2021) AAAS Fellow (2021) ASCI Member (2021) iCON Award (2019) Mukaiyama Award, Japan (2019) ACS Nobel Laureate Award for Graduate Education (2017) Thieme-IUPAC Prize in Synthetic Organic Chemistry (2014) Elias J. Corey Award (2013) Arthur C. Cope Scholar Award (2011) Research Output & Impact Burke has authored >120 peer-reviewed articles, >30 patents, and his work has been cited >20,000 times. High-impact publications in Nature , Science , and Angewandte Chemie have advanced automated synthesis, molecular prosthetics, and cystic fibrosis therapeutics. Laboratory & Training The Burke Laboratories house a multidisciplinary team of graduate students, post-doctoral researchers, and physician-scientists developing next-generation molecular prosthetics. The group is supported by NIH, NSF, private foundations, and industry partnerships aimed at democratizing molecular innovation.
Ron Dror is the Cheriton Family Professor of Computer Science at the Stanford Artificial Intelligence Lab , with courtesy appointments in Structural Biology and Molecular & Cellular Physiology . He also holds affiliations with Bio-X, the Institute for Human-Centered Artificial Intelligence (HAI), the Institute for Computational and Mathematical Engineering (ICME), Sarafan ChEM-H, and the Wu Tsai Neurosciences Institute. Education: PhD in Electrical Engineering and Computer Science, MIT MPhil in Biological Sciences, University of Cambridge (Churchill Scholar) BS in Mathematics and Electrical & Computer Engineering, Rice University (summa cum laude) Ron leads a multidisciplinary research group that combines molecular simulation and machine learning to study biomolecular structure, dynamics, and function. His work focuses on developing computational methods to accelerate drug discovery by predicting molecular interactions and designing more effective therapeutics. Current projects include the PENSA software library for analyzing biomolecular ensembles and FRAME framework for structure-based ligand design. His research has produced groundbreaking work on G-protein-coupled receptors (GPCRs) , RNA structure prediction , and mitochondrial transport mechanisms . Key publications highlight applications of geometric deep learning and molecular dynamics simulations in structural biology. Scientific Awards: Cheriton Family Professorship (2023) Two Gordon Bell Prizes (2014, 2009) Best Paper Awards at NeurIPS (2021), IPDPS (2013), SC11 (2011), SC09 (2009), SC06 (2006) Science Magazine Top 10 Breakthrough (2010) Fulbright Scholarship , NSF Fellowship , DoD Fellowship , Whitaker Foundation Fellowship Ron has advised numerous doctoral and master’s students including EJ Fine , Masha Karelina , and Briana Sobecks . His lab collaborates with experimentalists across academia and industry, applying computational methods to diverse biomedical problems such as RNA structure prediction , GPCR signaling , and mitochondrial metabolism .